Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.49 |
| ▸ | BTK | Q06187 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | CCR2 | P41597 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17766714 | 0.93 | TRPV1 (0.55) | TRPV1EPHX2KCNH2CACNA1CLMNA | |
| SCHEMBL17766730 | 0.91 | TRPV1 (0.56) | TRPV1EPHX2KCNH2CACNA1CLMNA | |
| SCHEMBL17766702 | 0.87 | TRPV1 (0.60) | TRPV1EPHX2KCNH2CACNA1CLMNA | |
| SCHEMBL19362086 | 0.86 | DHODH (0.60) | TRPV1EPHX2KCNH2CACNA1CMAPT | |
| SCHEMBL17766740 | 0.85 | TRPV1 (0.48) | TRPV1EPHX2KCNH2CACNA1CLMNA | |
| SCHEMBL17766784 | 0.85 | TRPV1 (0.53) | TRPV1EPHX2KCNH2CACNA1CLMNA | |
| SCHEMBL17766770 | 0.85 | TRPV1 (0.53) | TRPV1EPHX2KCNH2CACNA1CLMNA | |
| SCHEMBL17766728 | 0.85 | BTK (0.52) | TRPV1EPHX2KCNH2CACNA1CBTK | |
| SCHEMBL17766698 | 0.85 | TRPV1 (0.55) | TRPV1EPHX2KCNH2CACNA1CLMNA | |
| SCHEMBL16392266 | 0.85 | TRPV1 (0.52) | TRPV1EPHX2KCNH2CACNA1CLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771357-B2 | ALXR agonist compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-09-26 | — | — | US | disclosed |
| US-20160145249-A1 | ALXR AGONIST COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145249-A1 | ALXR AGONIST COMPOUND | MRGPRX2, MRGPRX1, MRGPRX4 | TRPV1 319/4885EPHX2 231/4885KCNH2 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.